Profound Medical Corp. 8-K

What Happened

• On March 27, 2026, Profound Medical Corp. filed a Form 8‑K to disclose a press release announcing that Texas Prostate, led by Dr. James Cochran, has reached its 100th TULSA Procedure™ performed in Dallas Medical Center’s MRI suite. The press release was furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: March 27, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Milestone: 100th TULSA Procedure performed by Texas Prostate at Dallas Medical Center.
• Press release: Exhibit 99.1 dated March 27, 2026 attached to the 8‑K.
• 8‑K was signed on behalf of Profound by CFO Rashed Dewan.

Why It Matters

• This disclosure highlights commercial and clinical adoption of Profound’s TULSA system — a concrete operational milestone that may support future sales and market awareness.
• The filing does not report earnings, revenue, or other financial results; it is a Reg FD disclosure of a business milestone, not a financial update.
• Investors tracking adoption metrics and procedure volume should view this as a signal of ongoing product use and provider engagement in the U.S. market; for financial impact, watch for future revenue or guidance disclosures.